Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
ALXN Hot Sheet
Rating Summary:9 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Bank of America initiates coverage on Alexion Pharmaceuticals (Nasdaq: ALXN) with a Neutral rating. Price target $53.
To see more analyst ratings on ALXN Click Here.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions.
To see more analyst ratings on ALXN Click Here.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Alexion Pharmaceuticals (ALXN) To Offer 5M Shares
- Canaccord Genuity Maintains a 'Hold' on Tiffany & Co. (TIF); Cutting PT and Estimates
Create E-mail Alert Related Categories
New CoverageRelated Entities
Bank of AmericaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
